Modality
Peptide
MOA
CDK4/6i
Target
IL-13
Pathway
Tau
UCT2DMCL
Development Pipeline
Preclinical
~Sep 2014
→ ~Dec 2015
Phase 1
~Mar 2016
→ ~Jun 2017
Phase 2
Sep 2017
→ Nov 2026
Phase 2Current
NCT08623581
2,429 pts·T2D
2017-09→2026-11·Not yet recruiting
2,429 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-11-107mo awayPh2 Data· T2D
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q4
P2
Not yet…
Catalysts
Ph2 Data
2026-11-10 · 7mo away
T2D
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08623581 | Phase 2 | T2D | Not yet recr... | 2429 | Mayo |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5767 | Pfizer | Phase 1/2 | BET | |
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| RHH-1969 | Roche | Approved | BET | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| Ivocapivasertib | Bristol-Myers Squibb | Phase 1 | BET | |
| Zorimavacamten | Bristol-Myers Squibb | Preclinical | Cl18.2 | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| Fixatenlimab | GSK | Phase 1/2 | JAK1 | |
| DSN-3066 | Daiichi Sankyo | Phase 3 | IL-13 | |
| VRT-4938 | Vertex Pharma | Preclinical | HER2 |